A “breakthrough” new three-drug combination offers hope for women battling an aggressive form of breast cancer, potentially extending their lives and delaying the need for chemotherapy, according to new research.
Experts suggest the treatment could become the "new go-to option" for individuals with PIK3CA-mutated hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, a condition where a mutation in the PIK3CA gene leads to uncontrolled cell division.
